Low‐Dose Thalidomide for Chemoprevention of Oral Leukoplakia: A Retrospective Observational Study
Oral Diseases · 2026
DOI: 10.1111/odi.70319 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Oral Diseases, 2026. Verfasst von Dan Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Thalidomide, Leukoplakia, Oral, Angiogenesis Inhibitors. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program, Research and Development Program, West China Hospital of Stomatology, Sichuan University.
Abstract (Originalsprache)
Background
Oral leukoplakia (OLK) lacks effective chemopreventive treatments. Thalidomide, with anti‐angiogenic, anti‐inflammatory, and immunomodulatory effects, may influence OLK progression. This study assessed feasibility and preliminary biological effects of low‐dose thalidomide on dysplasia and microvasculature.
Methods
A retrospective analysis was conducted on patients with OLK treated with thalidomide 50 mg/day for ≥ 30 days (2020–2024). The primary endpoint was change in dysplasia grade on paired biopsies. The secondary endpoint was change in intrapapillary capillary loop (IPCL) patterns on narrow‐band imaging (NBI). Lesion size was also recorded. Adverse events (AEs) were graded using CTCAE.
Results
Twenty‐eight patients were included, most with moderate to severe dysplasia. No patient showed ≥ 50% lesion size reduction, and all maintained stable clinical size. Among 13 patients with paired biopsies, 38.5% showed histological improvement, while 30.8% showed progression. In 25 patients with NBI, 52.0% had improved IPCL patterns, while 32.0% remained stable, and 16.0% worsened. AEs were reported in 32.1%, most commonly peripheral neuropathy (14.3%), with no treatment discontinuations.
Conclusions
Low‐dose thalidomide was feasible and well tolerated, showing biological activity by modulating dysplasia and IPCL patterns, despite minimal change in lesion size. These results support further prospective trials to confirm efficacy and refine treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Depar…
ORCID-Profile: Fangfang Qubie, Feifei Hou, Lu Jiang
Förderung
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Program
- Research and Development Program, West China Hospital of Stomatology, Sichuan University
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Liu, D., Xu, Y., Qiu, X., Zhou, S., Xin, Y., Yang, F., Cai, S., Ding, W., Qubie, F., Chen, T., Gong, Q., Huang, K., Hou, F., & Jiang, L. (2026). Low‐Dose Thalidomide for Chemoprevention of Oral Leukoplakia: A Retrospective Observational Study. Oral Diseases. https://doi.org/10.1111/odi.70319
Vancouver
Liu D, Xu Y, Qiu X, Zhou S, Xin Y, Yang F, et al. Low‐Dose Thalidomide for Chemoprevention of Oral Leukoplakia: A Retrospective Observational Study. Oral Diseases. 2026. doi:10.1111/odi.70319
BibTeX
@article{Liu2026,
author = {Liu, Dan and Xu, Yiming and Qiu, Xuemei and Zhou, Shuting and Xin, Yilin and Yang, Fan and Cai, Shuning and Ding, Wei and Qubie, Fangfang and Chen, Tingyu and Gong, Qianxi and Huang, Keyi and Hou, Feifei and Jiang, Lu},
title = {Low‐Dose Thalidomide for Chemoprevention of Oral Leukoplakia: A Retrospective Observational Study},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70319}
}
EUVIMED